Neutrophil to lymphocyte ratio predicts appropriate therapy in idiopathic dilated cardiomyopathy patients with primary prevention implantable cardioverter defibrillator

Fatih M. Uçar, MD, Burak Açar, MD.

ABSTRACT

Objectives: To investigate whether an inflammatory marker of neutrophil to lymphocyte ratio (NLR) predicts appropriate implantable cardioverter defibrillator (ICD) therapy (shock or anti-tachycardia pacing) in idiopathic dilated cardiomyopathy (IDC) patients.

Methods: We retrospectively examined IDC patients (mean age: 58.3 ± 11.8 years, 81.5% male) with ICD who admitted to outpatient clinic for pacemaker control at 2 tertiary care hospitals in Ankara and Edirne, Turkey from January 2013-2015. All ICDs were implanted for primary prevention. Hematological and biochemical parameters were measured prior procedure.

Results: Over a median follow-up period of 43 months (Range 7-125), 68 (33.1%) patients experienced appropriate ICD therapy. The NLR was increased in patients that received appropriate therapy (4.39 ± 2.94 versus 2.96 ± 1.97, p<0.001). To identify independent risk factors for appropriate therapy, a multivariate linear regression model was conducted and age (β=0.163, p=0.013), fasting glucose (β=0.158, p=0.017), C-reactive protein (CRP) (β=0.289, p<0.001) and NLR (β=0.212, p<0.008) were found to be independent risk factors for appropriate ICD therapy.

Conclusions: Before ICD implantation by using NLR and CRP, arrhythmic episodes may be predictable and better antiarrhythmic medical therapy optimization may protect these IDC patients from unwanted events.

Saudi Med J 2017; Vol. 38 (2): 143-148 doi: 10.15537/smj.2017.2.15929

From the Department of Cardiology (Uçar), Trakya University Hospital, Edirne, Department of Cardiology (Açar), Türkiye Yüksek İhtisas Training and Research Hospital, Ankara, Turkey.

Received 28th August 2016. Accepted 16th November 2016.

Address correspondence and reprint request to: Dr. Fatih Uçar, Department of Cardiology, Trakya University Hospital, Edirne, Turkey. E-mail: dr.fmucar@hotmail.com

ORCID: http://orcid.org/0000-0001-8123-4121

Disclosure. Authors have no conflict of interest, and the work was not supported or funded by any drug company.
The implantable cardioverter defibrillator (ICD) is an important treatment option for selected high-risk patients to reduce sudden cardiac death. Recent studies revealed that ICD implantation reduces mortality in heart failure patients with reduced left ventricular function. A significant amount of these patients receive appropriate or inappropriate ICD therapies and it has been shown that shocks cause impaired quality of life, psychiatric disturbances, and increased mortality. Therefore, it is important to identify high arrhythmic risk patients before ICD in order to avoid unwanted negative events. Hematological parameters are used as predictive and prognostic markers for cardiovascular diseases and neutrophil to lymphocyte ratio (NLR) has become a marker of underlying inflammation. Recent studies showed that NLR is a useful marker for predicting arrhythmic events. The aim of this study was to explore the association between NLR and appropriate ICD therapy [shock or anti tachycardia pacing (ATP)] in patients with idiopathic dilated cardiomyopathy (IDC) patients.

**Methods.** **Study population.** A total of 205 IDC patients (mean age: 58.3 ± 11.8 years, 81.5 % male) with ICD who referred to outpatient clinic for pacemaker control at 2 tertiary care hospitals in Edirne and Ankara, Turkey from January 2013-2015 were included in the study. The ICDs were implanted in Yuksek Ihtisas Hospital in Ankara, Turkey and Trakya University Hospital in Edirne, Turkey for primary prevention from 2003 to 2013 and the database of patients were reviewed retrospectively. The implanted devices were manufactured by Medtronic (Medtronic Inc., Minneapolis, MN, USA) and St. Jude (St. Jude Medical Inc. Sylmar, CA, USA) and all of them were single coil. Idiopathic dilated cardiomyopathy patients were selected for ICD implantation for primary prevention when Left ventricle ejection fraction ≤35% and symptomatic heart failure (NYHA II-III) despite ≥3 months of treatment with optimal medical therapy. The patients with ischemic cardiomyopathy, atrial fibrillation-flutter, coronary arterial disease, primary valvular pathology, advanced chronic obstructive pulmonary disease, persistent biventricular cardiac pacemaker, recent infection, malignancy, blood dyscrasia, autoimmune or inflammatory disease, renal failure, hepatic failure, or current therapy with corticosteroids, and nonsteroidal anti-inflammatory drugs were excluded from the study. Information, including age, gender, diabetes mellitus, hypertension, hyperlipidemia, and smoking status was gathered. Hypertension was defined as blood pressure >140/90 mm Hg on ≥2 occasions during office measurements or use of antihypertensive treatment. Diabetes mellitus was defined as fasting blood glucose >126 mg/dl or use of antidiabetics. Hyperlipidemia was considered to be present in patients with fasting total cholesterol ≥200 mg/dl or triglyceride ≥150 mg/dl. The study was in compliance with the principles outlined in the Declaration of Helsinki and was approved by the Institutional Ethics Committee.

**Laboratory.** Following a 12-hour fasting period, blood samples for the complete blood count analysis were collected before procedure in ethylenediaminetetraacetic acideanticoagulated Monovette tubes (Sarstedt, Leicester, United Kingdom). Total and differential leukocyte counts were measured by an automated hematology analyzer (Abbott Cell-Dyn 3700; Abbott Laboratory, Abbott Park, Illinois, USA). Fasting blood glucose was analysed using the hexokinase method. Serum level of C-reactive protein (CRP) was measured by rate turbidimetry on the Beckman Coulter (California, USA).

**Echocardiography.** All echocardiographic examinations were performed by a certified cardiologist experienced in this field using a Vivid-7 (GE Vingmed, Horten, Norway) device in compliance with American Society of Echocardiography (ASE) guidelines. Left ventricular ejection fraction was measured by using modified Simpson’s rule on apical 4-chamber views.

**Implantable cardioverter defibrillator Interrogation.** The end points for the study were appropriate ICD therapy (shock or ATP) due to ventricular tachyarrhythmia (Figure 1). Appropriate ICD therapy was defined as an antitachycardia pacing or shock therapy for ventricular tachycardia or fibrillation. All ICD’s zones were programmed as VT1 (167-182 bpm) with discriminators, VT2 (182-200 bpm) with discriminators, and VF (>200 bpm). The ICD programming included therapy for standard ventricular tachycardia (VT) with 3 antitachycardia bursts pacing...

![Figure 1 - Appropriate implantable cardioverter defibrillator therapy of a study patient.](image-url)
therapy combined with low-energy shock and for ventricular fibrillation (VF) shock therapy with a 300-ms cut-off cycle interval. Standard VT was defined as sustained tachycardia with a cycle interval ranging 300 to 360 ms. The VF was defined as when the cycle interval was shorter than 300 ms.

**Implantable cardioverter defibrillator Data Storage and Retrieval.** After ICD implantation the patients were followed up in our outpatient ICD clinic on 3 months intervals and when receiving high voltage therapy. The devices were interrogated at each controls and the complete set of data (including intracardiac electrograms) were recorded on USB flash memories and they were used in this study to retrieve all sustained arrhythmia episodes resulted in the ICD therapy. Two independent electrophysiologists Fatih Mehmet UCAR and Burak ACAR blinded to study design performed ICD interrogationsreviewed, and classified the arrhythmia episodes. In case of discrepancy in diagnosis the final analysis of the arrhythmia episode was made by a consensus of 3 electrophysiologists Fatih Mehmet UCAR, Burak ACAR and Serkan CAY After diagnosis arrhythmic event time and the therapy mode were recorded.

**Statistical analysis.** Continuous variables were expressed as mean ± standard deviation or as median with interquartile range; and categorical variables were expressed as number and percentages. A χ² test or Fisher’s exact test was performed to compare the categorical variables. Student’s t-test or Mann- Whitney U test was used for continuous variables, as appropriate. One-way analysis of variance (ANOVA) test was used to compare 3 groups of functional class. Independent associations between appropriate ICD therapy and independent variables included were in the multivariate regression model as covariates. Coefficients of standardized β regression along with their significance from the multivariate regression analysis were also reported. The Pearson correlation test was used for correlation analysis. Receiver operating curve (ROC) analysis was used to calculate the required NLR cut-off values to to detect appropriate ICD therapy (shock or ATP) with maximum sensitivity and specificity. All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL, USA) version 17. A p-value of less than 0.05 was considered statistically significant.

**Results.** Over a median follow-up period of 43 months (range 7-125), appropriate ICD therapies were observed in 68 (33.1%) of 205 IDC patients [shock 38 (55.9%) was patients, ATP 30 (44.1) patients]. The study population divided into 2 groups due to the presence of appropriate ICD therapy (control group: 137 patients and therapy group: 68 patients). The baseline characteristics of the study population are shown in Table 1. Baseline characteristics were similar between groups. The results of the hematological

### Table 1 - Baseline characteristics of the patients.

| Variables          | Control group (N=137) | ICD therapy group (n=68) | P-value |
|--------------------|-----------------------|--------------------------|---------|
| Male, N (%)        | (115) (83.9)          | (52) (76.4)              | 0.25    |
| Age                | 59 ± 11.1             | 56 ± 12.9                | 0.06    |
| Hypertension, n (%)| 70 (51)               | 38 (55)                  | 0.55    |
| Diabetes, n (%)    | 33 (24)               | 15 (22)                  | 0.86    |
| Smoking, n (%)     | 18 (13)               | 10 (14)                  | 0.83    |
| Heart rate in control | 72.7 ± 11.0          | 74.2 ± 12.6              | 0.36    |
| Ejection fraction (%) | 27 ± 5.9            | 27 ± 5.5                 | 0.99    |
| ACE-ARB, n (%)     | 104 (75.9)            | 56 (82.3)                | 0.37    |
| Spironolactone, n (%) | 67 (48.9)            | 39 (57.3)                | 0.29    |
| Digoxin, n (%)     | 33 (24.0)             | 18 (26.4)                | 0.73    |
| Diuretic, n (%)    | 99 (72.2)             | 45 (66.1)                | 0.41    |
| Beta-blocker, n (%)| 122 (89.0)            | 63 (92.6)                | 0.46    |
| Amiodarone, n (%)  | 9 (6.0)               | 10 (14.7)                | 0.07    |

### Table 2 - Comparison of patients with implantable cardioverter defibrillator (ICD) therapy and control individuals in terms of biochemical and hematological characteristics.

| Variables                | Control group (n=137) | ICD therapy group (n=68) | P-value |
|--------------------------|-----------------------|--------------------------|---------|
| Glucose, mg/dL           | 127 ± 63              | 113±31                   | 0.08    |
| Creatinine, mg/dL        | 1.05 ± 0.29           | 1.1±0.27                 | 0.09    |
| AST, U/L                 | 25 ± 18.5             | 22±9.0                   | 0.17    |
| ALT, U/L                 | 23 ± 14.9             | 21±10.7                  | 0.32    |
| LDL, mg/dL               | 99.2 ± 32.3           | 105±36.4                 | 0.42    |
| HDL, mg/dL               | 44.6 ± 10.6           | 45.7±15.3                | 0.69    |
| Hemoglobin, g/dL         | 13.4 ± 2.8            | 13.8±2.0                 | 0.25    |
| Platelet, x10⁹/L         | 235 ± 61              | 229±71                   | 0.53    |
| WBC, x10⁹/L              | 8.5 ± 2.3             | 8.4±2.2                  | 0.97    |
| Neutrophil, x10⁹/L       | 5.3 ± 1.7             | 6.0±2.1                  | 0.01    |
| Lymphocyte, x10⁹/L       | 2.0 ± 0.72            | 1.6±0.62                 | <0.001  |
| NLR                      | 2.96±1.97             | 4.39±2.94                | <0.001  |
| CRP mg/dL                | 2.9 ± 3.9             | 6.9±5.7                  | <0.001  |

Data mean ± standard deviation or number of patient, ALT - Alanine aminotransferase, AST - aspartate aminotransferase, LDL - Low-density lipoprotein, HDL - High-density lipoprotein, WBC - White blood cell, NLR - Neutrophil to lymphocyte ratio, CRP - C-reactive protein.
NLR predicts therapy in IDC patients with ICD ... Uçar & Açar

and biochemical parameters are listed in Table 2. The NLR levels were higher in the therapy group patients (4.39 ± 2.94) compared with the control group (2.96 ± 1.97) \( p<0.001 \). Additionally the CRP in therapy group patients was \( 11.0 ± 7.9 \) and in control group \( 4.4 ± 4.6 \) \( p<0.001 \), and the neutrophil in the therapy group patients was \( 6.0 ± 2.1 \) and in the control group \( 5.3 ± 1.7 \) \( p=0.01 \) levels were higher in therapy group when compared control group. To identify in dependent risk factors for ICD therapy, a multivariate linear regression model was conducted that included the following covariates: age, amiodarone use, glucose, creatinine, neutrophil, CRP, and NLR. Age \( (\beta=0.163, p=0.013) \), glucose \( (\beta=0.158, p=0.017) \), CRP \( (\beta=0.289, p<0.001) \) and NLR \( (\beta=0.212, p<0.008) \) levels were found to be independent risk factors for appropriate ICD therapy. Pre-procedural NLR were found to correlate with CRP values \( (r=0.243, p<0.001) \) (Figure 2).

Receiver operating characteristic curves were used to explore the relation between preprocedural ICD implantation NLR and appropriate ICD therapy. The area under the curve was 0.707 (95% Confidence interval: 0.629 to 0.785, \( p<0.001 \)). Using a cutoff level of 2.93, the preprocedural NLR predicted appropriate ICD therapy with a sensitivity of 71% and specificity of 62% (Figure 3).

**Discussion.** In our study, we investigate whether NLR in IDC patients with primarily implanted ICD is a predictor of appropriate therapy (shock or ATP). In the average follow up of 43 months (7-125) we found that there is a strong association with appropriate therapy and NLR. However, the number of lymphocytes and neutrophil and CRP levels also showed a strong relationship with the appropriate ICD therapy. Effectiveness of the ICD therapy is assessed by identifying life-threatening rhythm disorders and treating it appropriately. Although ICD has mortality reduction effect, it can cause various complications. Inappropriate shocks are associated with high mortality and morbidity.\(^5\) However, inappropriate shocks cause impaired quality of life, psychiatric disturbances, and increased mortality. So the implantation of ICD to eligible patients is very important.

The IDC is an inflammatory disease with many circulating active cytokines being involved in the pathogenesis. Although the mechanisms responsible for the development of IDC are not fully understood, high production of inflammatory cytokines in leukocytes of patients with IDC and the presence of interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-\(\alpha\)) in the cardiac tissue suggest an inflammatory component in the disease development and progression.\(^{18}\) The relationship between inflammation and mortality is well known in heart failure patients.\(^{11}\) The effects of inflammation and neurohormonal activation in cardiovascular diseases and strong relationship in heart failure and atherosclerosis has been demonstrated in studies. These studies have demonstrated that these mediators are predictors of atrial and ventricular arrhythmias.\(^{19,20}\) Serum collagen turn over markers were shown a predictor of appropriate shock in primarily implanted ICD with IDC patients. These markers are associated with ventricular remodeling and electrical activity of ventricle.\(^{21}\) Another study showed that BNP and nt-BNP levels before ICD implantation are associated with appropriate ICD shocks and BNP may serve as a marker of mechanoelectrical feedback in cardiomyocytes under certain conditions.\(^{22}\) Inflammation is a controversial factor of appropriate ICD shocks. While
some previous studies emphasized that IL-6 and CRP are appropriate ICD shock predictors,23,24 others have not.25 In a study by Cheng et al,26 it is observed that appropriate ICD shock rates increased with high IL-6 levels. However, CRP, IL-6, TNF-α, pro-BNP showed a linear progression of the increase of mortality in IDC patients and a scoring system, which created with the combined use of these markers has been shown to be a strong predictor for appropriate ICD shocks and mortality. Inflammatory response play a key role in the pathophysiology of many vascular disorders of both heart and brain.27,28 Neutrophil infiltration in the atherosclerotic plaques allows prediction of the risk of plaque rupture29,30 and activated neutrophils lead to plaque rupture through the effects of various proteolytic enzymes and myeloperoxidase-like oxidants.31,32 Lymphocytopenia is a common finding during the stress response secondary to increased corticosteroids levels.33 In recent years, an index which reflects both neutrophils in acute inflammation that reflects the height of the situation and lymphopenia after acute physiological stress has been used. This index obtained by the ratio of neutrophils and lymphocytes, was used with other inflammatory markers in studies and has been determined as a good indicator of inflammation.14

Previous studies34,35 demonstrated the relationship between NLR and functional capacity and the severity of the disease in IDC patients34,35. And it has been revealed that NLR is a good marker for predicting atrial and ventricular arrhythmias.13,15,36. The ICD implantation to IDC patients for primary prophylaxis is controversial. In a Danish Study,37 it was observed that incidence of all-cause mortality was similar in the ICD group versus control group, and younger patients (<59 years) appeared to derive greater benefit from the ICD implantation versus older patients. In the present study, patients’ average age was 58.3 and it can be said that they were young. We found a significant relationship between increased NLR and appropriate therapy in IDC patients before ICD implantation. Additionally, CRP levels were high similar to NLR. Therefore, our findings may be beneficial for the selection of IDC patients for primary prevention ICD implantation.

The study was single-centered and included limited number of patients. Due to the sample size and inadequate power, it is possible that some associations were not detected. Other inflammatory parameters such as IL-6 or TNF-α were not measured. Ischemic cardiomyopathy patients were not involved to study. Further prospective studies are needed to confirm the prognostic role of inflammatory markers for appropriate shock in IDC patients with ICD.

In conclusion, NLR predicts arrhythmic events and appropriate ICD therapy in IDC patients with primary prophylaxis implanted ICD. Our results suggest that NLR and CRP may be used as biomarkers for arrhythmic risk stratification and medical therapy optimization should be carried out better especially in high risk patients.

Acknowledgment. The authors gratefully acknowledge Dr. Serkan Cay, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey for his help in diagnosis the final analysis of the arrhythmia episodes.

References

1. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237.
2. Hua W, Niu H, Fan X, Ding L, Xu YZ, Wang J, et al. Group ICDS: Preventive effectiveness of implantable cardioverter defibrillator in reducing sudden cardiac death in the Chinese population: a multicenter trial of ICD therapy versus non-ICD therapy. J Cardiovasc Electrophysiol 2012; Suppl 1: S5-S9.
3. Moss AJ, Hall WJ, Cannon DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335: 1933-1940.
4. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannon DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.
5. Daubert JP, Zareba W, Cannon DS, McNitt S, Rosero SZ, Wang P, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008; 51: 1357-1365.
6. Thavikulwat AC, Tomson TT, Knight BP, Bonow RO, Choudhury L. Appropriate Implantable Defibrillator Therapy in Adults with Hypertrophic Cardiomyopathy. J Cardiovasc Electrophysiol 2016; 27: 953-960.
7. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008; 359: 1009-1017.
8. Vollmann D, Luthje L, Vonhof S, Unterberg C. Inappropriate therapy and fatal proarrhythmia by an implantable cardioverter-defibrillator. Heart rhythm 2005; 2: 307-309.
9. Aribas A, Akilli H, Gul EE, Kayrak M, Demir K, Duman C, et al. Can neutrophil/lymphocyte ratio predict recurrence of non-valvular atrial fibrillation after cardioversion? Anatolou Kardiyo Derg 2013; 13: 123-130.
10. Kaya H, Ertas F, Islamoglu Y, Kaya Z, Arilgan ZA, Cil H, et al. Association between neutrophil to lymphocyte ratio and severity of coronary artery disease. Clin Appl Thromb Hemost 2014; 20: 50-54.
11. Uşחambahingam S, Parvathnan EA, Subramanian S, Ahmed W, Martin W, Daley M, et al. Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. Am J Cardiol 2011; 107: 433-438.
12. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurum HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. *Am J Cardiol* 2008; 102: 653-657.

13. Chatterjee S, Chandra P, Guha G, Kalva V, Chakraborty A, Frankel R, et al. Pre-procedural Elevated White Blood Cell Count and Neutrophil-Lymphocyte (N/L) Ratio are Predictors of Ventricular Arrhythmias During Percutaneous Coronary Intervention. *Cardiovasc Hematol Disorders Target Treat* 2011; 11: 58-60.

14. Gibson PH, Cuthbertson BH, Croal BL, Rae D, El-Shafei H, Gibson G, et al. Usefulness of neutrophil/lymphocyte ratio as predictor of new-onset atrial fibrillation after coronary artery bypass grafting. *Am J Cardiol* 2010; 105: 186-191.

15. Shao Q, Chen K, Rha SW, Lim HE, Li G, Liu T. Usefulness of Neutrophil/Lymphocyte Ratio as a Predictor of Atrial Fibrillation: A Meta-analysis. *Arch Med Res* 2015; 46: 199-206.

16. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2012; 33: 1787-1847.

17. American College of Cardiology Foundation Appropriat Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, et al. ACCF/AHA/ASNC/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography, A Report of the American College of Cardiology Foundation Appropriat Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance American College of Chest Physicians. *J Am Soc Echocardiogr* 2011; 24: 229-267.

18. Hoge M, Mandi Y, Csany M, Sepp R, Buzas K. Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. *Am J Cardiol* 2004; 94: 249-251.

19. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. *Circulation* 2002; 105: 2595-2599.

20. Bruins P, te Velthuis H, Yazdanbaksh AP, Jansen PG, van Hardeveld FW, de Beaumont EM, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postoperative activation involves C-reactive protein and is associated with postoperative arrhythmia. *Circulation* 1997; 96: 3542-3548.

21. Kanoupakis EM, Manios EG, Kallergis EM, Mavrakis HE, Goudis CA, Saloustros IG, et al. Serum markers of collagen turnover predict future shocks in implantable cardioverter-defibrillator recipients with dilated cardiomyopathy on optimal treatment. *J Am Coll Cardiol* 2010; 55: 2753-2759.

22. Levine YC, Rosenberg MA, Mittleman M, Samuel M, Methachithiphan N, Link M, et al. B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias. *Heart Rhythm* 2014; 11: 1109-1116.

23. Streitner F, Kusczyk J, Veltmann C, Brueckmann M, Streitner I, Brade J, et al. Prospective study of interleukin-6 and the risk of malignant ventricular tachyarrrhythmia in ICD-recipients—a pilot study. *Cytokine* 2007; 40: 30-34.

24. Theuns DA, Smith T, Szili-Torok T, Muskens-Heemskerk A, Janse P, Jordans L. Prognostic role of high-sensitivity C-reactive protein and B-type natriuretic peptide in implantable cardioverter-defibrillator patients. *Pacing Clin Electrophysiol* 2012; 35: 275-282.

25. Flevari P, Theodorakis G, Leftheriotis D, Kroupis C, Kolokathis F, Dima K, et al. Serum markers of deranged myocardial collagen turnover: their relation to malignant ventricular arhythmias in cardioverter-defibrillator recipients with heart failure. *Am Heart J* 2012; 164: 530-537.

26. Cheng A, Zhang Y, Blasco-Colmenares E, Dalal D, Butcher B, Norgard S, et al. Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD). *Circ Arrhythm Electrophysiol* 2014; 7: 1084-1091.

27. Kökdü E, Yüksek IO, Arslan Ş, Bayar N, Çagırıcı G, Gencer ES, et al. Is Elevated Neutrophil-to-Lymphocyte Ratio a Predictor of Stroke in Patients with Intermediate Carotid Artery Stenosis? *J Stroke Cerebrovasc Dis* 2016; 25: 578-584.

28. Larntz S, Cagnetti C, Provenzali L, Silvestrini M. Neutrophil-to-Lymphocyte Ratio Predicts the Outcome of Acute Intracerebral Hemorrhage. *Stroke* 2016; 47: 1654-1657.

29. Rotzius P, Thams S, Soehnlein O, Kenne E, Tseng CN, Björkström NK, et al. Distinct infiltration of neutrophils in lesion shoulders in ApoE−/− mice. *Am J Pathol* 2010; 177: 493-500.

30. Drechsler M, Megens RT, van Zandvoort M, Weber C, Soehnlein O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. *Circulation* 2010; 122: 1837-1845.

31. Ndrepepa G, Braun S, Mehilli J, von Beckerath N, Schömig A, Kastrati A. Myeloperoxidase level in patients with stable early atherosclerosis. *Clin Invest* 2015; 48: 202-208.

32. Yildiz A, Yuksel M, Oylumlu M, Polat N, Akil MA, Acet H. The association between the neutrophil/lymphocyte ratio and functional capacity in patients with idiopathic dilated cardiomyopathy. *Anatol J Cardiol* 2015; 15: 13-17.

33. Yildiz A, Oylumlu M, Yuksel M, Aydin M, Polat N, Acet H, et al. The Association Between the Neutrophil-to-Lymphocyte Ratio and the Presence of Ventricular Premature Contractions in Some Human Blood Lymphocyte Subpopulations. *J Leukoc Biol* 2007; 82: 1420-1429.

34. Onsrud M, Thorsby E. Influence of in vivo hydrocortisone on some human blood lymphocyte subpopulations. I. Effect on natural killer cell activity. *Scand J Immunol* 1981; 13: 573-579.

35. Avci A, Alizade E, Fidan S, Yesin M, Guler Y, Kargin R, et al. Neutrophil/lymphocyte ratio is related to the severity of idiopathic dilated cardiomyopathy. *Scand Cardiovasc J* 2014; 48: 202-208.

36. Thune JJ, Pehrson S, Nielsen JC, Haarbo J, Videbak L, Korup E, et al. Rationale, design, and baseline characteristics of the DANish randomized, controlled, multicenter study to assess the efficacy of Implantable Cardioverter Defibrillators in patients with non-ischemic Systolic Heart failure on mortality (DANISH). *Am Heart J* 2016; 179: 136-141.